Annovis Bio, Inc. (ANVS)Healthcare | Biotechnology | Malvern, United States | NYSE
1.86 USD
-0.06
(-3.125%) ⇩
(April 21, 2026, 4 p.m.
EDT)
|
Hot Take ↕ | April 19, 2026, 12:34 a.m. EDT
Annovis Bio presents a classic 'dilution trap' scenario masked by speculative long-term call buying. The company just raised $10M via a registered direct offering, causing the stock to drop 26% on the news. While analysts rate it a 'strong buy' based on potential Alzheimer's drug milestone, the fundamentals—negative cash flow, negative ROE, and negative future EPS—are starkly negative. Speculators are betting the long-term catalyst (the drug) will rally the stock to the $5.00 targets, but tactical traders are buying puts to protect against the dilution and pre-earnings volatility. For a short-term investor, the immediate catalyst is negative (cap dilution), making a 2-star rating appropriate with a wait-and-see stance. |
| Model | MAE |
|---|---|
| AutoETS ✓ | 0.125466 |
| MSTL | 0.130244 |
| AutoTheta | 0.256469 |
| AutoARIMA | 0.610460 |
Forecast horizon: 45 days | Selected: AutoETS
| Forecast Reliability | |
|---|---|
| Score | 22% |
| H-stat | 5.39 |
| Ljung-Box p | 0.000 |
| Jarque-Bera p | 0.000 |
| Excess Kurtosis | 2.60 |
| Attribute | Value |
|---|---|
| Sector | Healthcare |
| Market Cap | 64,230,248 |
| Forward P/E | -1.37 |
| Beta | 1.36 |
| Website | https://www.annovisbio.com |
As of April 19, 2026, 12:34 a.m. EDT: Options data reveals a conflict between short-term hedging and medium-term speculation. The April 17 expiration (near-term) shows significant put open interest (OI) relative to volume at the $2.50 and $2.00 strikes (480 and 104 respectively vs low volume), suggesting downside protection is being purchased around current price levels. Conversely, significant Call OI exists at the $5.00 strike, primarily in May and October expirations, indicating a bullish expectation for a move toward $5.00 by the first half of 2027. The April 24 calls show unusual activity with 'New Flow' at the $2.5 strike (Vol > OI), hinting at some immediate upside sentiment, but the heavy near-term put accumulation suggests the market is primarily positioning for stabilization or a short-term decline despite the long-term gamma exposure at $5.00.
| Attribute | Value |
|---|---|
| 52 Week Change | 0.23178804 |
| Address1 | 101 Lindenwood Drive |
| Address2 | Suite 225 |
| All Time High | 132.0 |
| All Time Low | 1.11 |
| Ask | 2.05 |
| Ask Size | 500 |
| Average Analyst Rating | 1.5 - Strong Buy |
| Average Daily Volume10 Day | 1,853,970 |
| Average Daily Volume3 Month | 665,888 |
| Average Volume | 665,888 |
| Average Volume10Days | 1,853,970 |
| Beta | 1.363 |
| Bid | 1.8 |
| Bid Size | 500 |
| Book Value | 0.62 |
| City | Malvern |
| Compensation As Of Epoch Date | 1,735,603,200 |
| Country | United States |
| Crypto Tradeable | 0 |
| Currency | USD |
| Current Price | 1.86 |
| Current Ratio | 5.799 |
| Custom Price Alert Confidence | HIGH |
| Date Short Interest | 1,774,915,200 |
| Day High | 1.97 |
| Day Low | 1.85 |
| Display Name | Annovis Bio |
| Earnings Timestamp End | 1,755,547,200 |
| Earnings Timestamp Start | 1,755,028,800 |
| Ebitda Margins | 0.0 |
| Enterprise Value | 33,208,450 |
| Eps Current Year | -1.14 |
| Eps Forward | -1.36 |
| Eps Trailing Twelve Months | -1.4 |
| Esg Populated | 0 |
| Exchange | NYQ |
| Exchange Data Delayed By | 0 |
| Exchange Timezone Name | America/New_York |
| Exchange Timezone Short Name | EDT |
| Fifty Day Average | 2.3328 |
| Fifty Day Average Change | -0.4727999 |
| Fifty Day Average Change Percent | -0.20267487 |
| Fifty Two Week Change Percent | 23.178804 |
| Fifty Two Week High | 5.5 |
| Fifty Two Week High Change | -3.6399999 |
| Fifty Two Week High Change Percent | -0.66181815 |
| Fifty Two Week Low | 1.36 |
| Fifty Two Week Low Change | 0.5 |
| Fifty Two Week Low Change Percent | 0.36764705 |
| Fifty Two Week Range | 1.36 - 5.5 |
| Financial Currency | USD |
| First Trade Date Milliseconds | 1,580,308,200,000 |
| Float Shares | 24,406,792 |
| Forward Eps | -1.36 |
| Forward P E | -1.367647 |
| Free Cashflow | -15,183,042 |
| Full Exchange Name | NYSE |
| Full Time Employees | 7 |
| Gmt Off Set Milliseconds | -14,400,000 |
| Gross Margins | 0.0 |
| Has Pre Post Market Data | 1 |
| Held Percent Insiders | 0.16429001 |
| Held Percent Institutions | 0.18041 |
| Implied Shares Outstanding | 34,532,394 |
| Industry | Biotechnology |
| Industry Disp | Biotechnology |
| Industry Key | biotechnology |
| Is Earnings Date Estimate | 1 |
| Language | en-US |
| Last Fiscal Year End | 1,767,139,200 |
| Long Business Summary | Annovis Bio, Inc., a clinical stage drug platform company, develops drugs to treat neurodegeneration in the United States. The company's lead product candidate is Buntanetap, which is in phase 3 to treat alzheimer's disease, as well as in open-label phase 3 to treat parkinson's disease. It also develops ANVS405, which is in phase 2 and 3 clinical trials for the treatment of traumatic brain injury and/or stroke; and ANVS301, which finished phase 1 clinical trial developed to increase cognitive capability in later stages of alzheimer's disease and dementia. Annovis Bio, Inc. was incorporated in 2008 and is headquartered in Malvern, Pennsylvania. |
| Long Name | Annovis Bio, Inc. |
| Market | us_market |
| Market Cap | 64,230,248 |
| Market State | PRE |
| Max Age | 86,400 |
| Message Board Id | finmb_622711087 |
| Most Recent Quarter | 1,767,139,200 |
| Net Income To Common | -28,854,196 |
| Next Fiscal Year End | 1,798,675,200 |
| Non Diluted Market Cap | 64,230,250 |
| Number Of Analyst Opinions | 2 |
| Open | 1.9 |
| Operating Cashflow | -25,619,704 |
| Operating Margins | 0.0 |
| Payout Ratio | 0.0 |
| Phone | 484 875 3192 |
| Pre Market Change | -0.03999996 |
| Pre Market Change Percent | -2.1505356 |
| Pre Market Price | 1.82 |
| Pre Market Time | 1,776,847,732 |
| Previous Close | 1.92 |
| Price Eps Current Year | -1.6315789 |
| Price Hint | 4 |
| Price To Book | 3.0 |
| Profit Margins | 0.0 |
| Quick Ratio | 5.373 |
| Quote Source Name | Delayed Quote |
| Quote Type | EQUITY |
| Recommendation Key | strong_buy |
| Recommendation Mean | 1.5 |
| Region | US |
| Regular Market Change | -0.0599999 |
| Regular Market Change Percent | -3.125 |
| Regular Market Day High | 1.97 |
| Regular Market Day Low | 1.85 |
| Regular Market Day Range | 1.85 - 1.97 |
| Regular Market Open | 1.9 |
| Regular Market Previous Close | 1.92 |
| Regular Market Price | 1.86 |
| Regular Market Time | 1,776,801,602 |
| Regular Market Volume | 901,886 |
| Return On Assets | -1.0603299 |
| Return On Equity | -2.20607 |
| Sand P52 Week Change | 0.3140242 |
| Sector | Healthcare |
| Sector Disp | Healthcare |
| Sector Key | healthcare |
| Shares Outstanding | 34,532,393 |
| Shares Percent Shares Out | 0.1141 |
| Shares Short | 3,234,406 |
| Shares Short Previous Month Date | 1,772,150,400 |
| Shares Short Prior Month | 2,745,085 |
| Short Name | Annovis Bio, Inc. |
| Short Percent Of Float | 0.1265 |
| Short Ratio | 7.78 |
| Source Interval | 15 |
| State | PA |
| Symbol | ANVS |
| Target High Price | 17.0 |
| Target Low Price | 8.0 |
| Target Mean Price | 12.5 |
| Target Median Price | 12.5 |
| Total Cash | 19,532,338 |
| Total Cash Per Share | 0.689 |
| Total Debt | 0 |
| Tradeable | 0 |
| Trailing Annual Dividend Rate | 0.0 |
| Trailing Annual Dividend Yield | 0.0 |
| Trailing Eps | -1.4 |
| Trailing Peg Ratio | None |
| Triggerable | 1 |
| Two Hundred Day Average | 2.6983 |
| Two Hundred Day Average Change | -0.8382999 |
| Two Hundred Day Average Change Percent | -0.31067705 |
| Type Disp | Equity |
| Volume | 901,886 |
| Website | https://www.annovisbio.com |
| Zip | 19,355 |